Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Agenix to Acquire Diagnostic Device Technology from Tyrian

Published: Thursday, October 25, 2012
Last Updated: Thursday, October 25, 2012
Bookmark and Share
Acquisition of diagnostic device will expand Agenix’s drug and diagnostic pipeline.

Agenix Limited has announced that it had entered an agreement with Tyrian Diagnostics Limited to license its rapid point-of-care human diagnostic technology in a share exchange transaction.

Under the terms of the agreement, Agenix will license exclusive world-wide royalty free rights to the human health application for Tyrian’s proprietary DiagnostIQ® rapid point-of-care test platform.

In return, Agenix will provide Tyrian with Agenix shares to the value of $0.5million payable in installments to be completed by June 2014.

The DiagnostIQ® platform comprises a patented disposable test device which can be used for various applications either alone or together with the DiagnostIQ® Reader for various human, animal and agricultural applications to determine action to be taken at the point of care for human and veterinary tests or point of need for agricultural and environmental tests.

Agenix has licensed the rights to develop the DiagnostIQ® platform for human health applications and aims to develop the technology into a micro-array device so that it will process multiple human health diagnostic tests on the one system.

The device is currently licensed to Bayer CropScience AG for an agricultural application.

In an addition to the license, to be finalized in the near future, Agenix will also acquire a patent for Tyrian’s antibody-based test for active tuberculosis.

This patent covers a novel biomarker, discovered by Tyrian, which has the potential to distinguish patients with active TB infection from those that have been infected in the past, or have been vaccinated.

Agenix Limited Chairman and Chief Executive Officer Nicholas Weston said, “This acquisition advances our product pipeline and adds to our human health diagnostics business. We now have a platform for human health array and micro-array technology developers globally, as well as a medical device product for our expanding China business.”

Tyrian Limited Chairman, Roger Amos said the license agreement with Agenix was part of the company’s continued efforts by Tyrian to monetize its diagnostic testing assets following the recent company restructuring. It follows a 2011 license to SpeeDx Pty Ltd for active TB testing approaches outside of the antibody field.

Mr Weston said Agenix did not anticipate the closing of the deal would impact its immediate cash requirements.

The shares to be issued to Tyrian currently represent less than 20% of the issued capital and will be fully paid ordinary shares ranking equally with existing listed shares.

The share issue will be made within Agenix’s 15% annual placement capacity under ASX Listing Rule 7.1 and will not require shareholder approval.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

New Patent Granted in Japan
New patent enhances value of revolutionary new Australian blood clot diagnostic technology.
Tuesday, October 30, 2012
New Patent Granted in Japan Enhances Value of Diagnostic Technology
Japan's patent granted for ThromboView technology.
Monday, May 21, 2012
Scientific News
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Inflammation Linked to Colon Cancer Metastasis
A new Arizona State University research study led by Biodesign Institute executive director Raymond DuBois has identified for the first time the details of how inflammation triggers colon cancer cells to spread to other organs, or metastasize.
New Strategy for Combating Adenoviruses
Using an animal model they developed, Saint Louis University and Utah State university researchers have identified a strategy that could keep a common group of viruses called adenoviruses from replicating and causing sickness in humans.
Major Advance Toward More Effective, Long-Lasting Flu Vaccine
Collaboration shows vaccine candidate can produce powerful ‘broadly neutralizing antibodies’ in animal models.
Immune System: Help for Killer Cells
A study from the University of Bonn may show the way to more effective vaccines.
Protein Found to Control Inflammatory Response
A new Northwestern Medicine study shows that a protein called POP1 prevents severe inflammation and, potentially, diseases caused by excessive inflammatory responses.
A Leap Forward in Vaccinating Against HIV
A team of scientists has developed an experimental vaccine candidate that successfully stimulates the immune system activity in animal models necessary to stop HIV infection.
MRI Scanners Can Steer Therapeutics to Specific Target Sites
Scientists from the University of Sheffield have discovered MRI scanners, normally used to produce images, can steer cell-based, tumour busting therapies to specific target sites in the body.
Agricultural Intervention Improves HIV Outcomes
A multifaceted farming intervention can reduce food insecurity while improving HIV outcomes in patients in Kenya, according to a randomized, controlled trial led by researchers at UC San Francisco.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!